| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-099 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 15 日（星期一）至 9 月 19 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600521@huahaipharm.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江华海药业股份有限公司（以下简称"公司"）已于 2025 年 8 月 26 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 9 月 22 日（星期一）16:00-17:00 举行 2025 年半年度业绩说明会，就投资者关心的 ...

Group 1 - The core viewpoint of the articles highlights the increasing importance of domestic chip production in China, particularly in the context of AI model training and the ongoing geopolitical tensions affecting chip supply chains [1][2] - Alibaba and Baidu have begun using self-designed chips for AI model training, indicating a shift towards domestic chip alternatives to NVIDIA products [1] - The general computing power's share is declining, while intelligent computing power, essential for AI training and inference, is becoming the growth core [1] Group 2 - The domestic computing power industry chain is presented with opportunities due to U.S. restrictions on advanced chip exports to China, increasing the urgency for domestic chip replacement [2] - The long-term trend indicates that the design, production, and mass production of high-end AI chips in China is becoming a necessity [2] - The CSI 500 Quality Growth Index consists of 100 companies selected for their strong profitability, sustainable earnings, and robust cash flow, providing diverse investment options [2] Group 3 - As of August 29, 2025, the top ten weighted stocks in the CSI 500 Quality Growth Index accounted for 21.48% of the index, with notable companies including Dongwu Securities and Huagong Technology [2][4] - The CSI 500 Quality Growth ETF closely tracks the CSI 500 Quality Growth Index, offering investors a diversified investment vehicle [2]

Group 1 - The core viewpoint of the article highlights a rebound in the innovative drug sector, with notable stock performances from companies like Zhaoyan New Drug, which achieved three consecutive trading limits in six days [1] - The National Medical Products Administration (NMPA) has proposed to further optimize the review and approval process for clinical trials of innovative drugs, aiming to complete the review and approval within 30 working days for eligible applications [1] - This new pathway supports key national research and development projects, encourages early global synchronization of research, and facilitates international multi-center clinical trials to address urgent clinical needs and promote the development of the national pharmaceutical industry [1] Group 2 - Companies such as Yuandong Biological and Saily Medical have seen significant stock price increases, with Yuandong Biological rising over 10% and Saily Medical hitting the daily limit [1] - Other companies in the sector, including Warner Pharmaceuticals, Haoyuan Pharmaceutical, and Huahai Pharmaceutical, also experienced notable gains, indicating a broader positive trend in the innovative drug market [1]

Group 1 - The innovative drug concept stocks are showing strength, with Seer Medical hitting the daily limit up [1] - Guangsheng Tang increased by over 7%, indicating positive market sentiment [1] - Other companies such as Yuandong Biological, Huahai Pharmaceutical, Zhaoyan New Drug, and Enhua Pharmaceutical also experienced upward movement [1]

Core Insights - The market demand for chitosan is increasing due to growing concerns about food safety, healthcare, and environmental protection, with the market size in China projected to reach 758 million yuan in 2024, representing a year-on-year growth of 19.37% [1][7]. Industry Overview - Chitosan is a natural biodegradable biopolymer derived from chitin, primarily sourced from the shells of crustaceans and certain fungi and plants [2][4]. - The unique physical and chemical properties of chitosan, influenced by its degree of deacetylation, allow for a wide range of applications across various sectors [2][4]. Industry Chain - The upstream of the chitosan industry includes raw materials such as crustacean shells, insects, fungi, and chemicals like hydrochloric acid and sodium hydroxide [5]. - The midstream involves the production and manufacturing of chitosan, while the downstream applications span pharmaceuticals, food preservation, cosmetics, environmental protection, agriculture, textiles, and paper [5][6]. Market Size - The chitosan industry in China is expected to grow significantly, with applications in food preservation, medical materials, and as an eco-friendly alternative to traditional plastics [1][7]. Key Companies - Jiangsu Kangting Biotechnology Co., Ltd. is a major player in the chitosan industry, focusing on research, production, and sales, with a wide range of applications in health foods, medical devices, and agriculture [8][9]. - Shandong Weikang Biomedical Technology Co., Ltd. specializes in marine sugar bioengineering, emphasizing research and development in chitosan and its derivatives [9]. Industry Development Trends 1. Continuous technological innovation is crucial for industry upgrades, with new extraction methods like enzyme extraction and supercritical fluid extraction expected to replace traditional methods [10][11]. 2. The application of chitosan is expanding into emerging fields beyond traditional sectors, including its use as a natural preservative and in high-end medical products [10][11]. 3. The industry's strategic value is highlighted by the push for sustainable development and carbon neutrality, with international competition driving technological upgrades and collaborations [11].

Investment Rating - The report maintains an "Accumulate" rating for the company [6][13]. Core Views - The company's Q2 2025 non-GAAP profit exceeded expectations, driven by the volume increase of Didasun and the gradual advancement of its innovative pipeline, indicating a positive outlook for its transformation into innovation [2][13]. Financial Summary - Total revenue for H1 2025 was 2.017 billion yuan, a decrease of 6.2% year-on-year, while net profit attributable to the parent company was 388 million yuan, down 3.5%. The non-GAAP net profit was 360 million yuan, an increase of 7.8%. The gross margin was 49.6%, down 2.0 percentage points [13]. - For Q2 2025, the single-quarter revenue was 1.06 billion yuan, a decrease of 2.6%, with a net profit of 225 million yuan, down 2.7%. The non-GAAP net profit was 214 million yuan, an increase of 20.4%, and the gross margin was 51.2%, down 0.03 percentage points [13]. - The company adjusted its EPS forecasts for 2025-2026 to 0.94 and 1.09 yuan respectively, with a new forecast for 2027 at 1.30 yuan. The target price was raised to 27.25 yuan based on a 25x PE for 2026 [13]. Business Performance - The main business remains stable, with the finished drug revenue for H1 2025 at 1.175 billion yuan, down 9.7%. However, foreign trade revenue grew over 30.1%. The innovative drug Didasun had its first year of insurance coverage, generating 55 million yuan in revenue during the reporting period [13]. - The raw material drug segment reported revenue of 453 million yuan, down 9.6%, while the medical device segment saw revenue of 349 million yuan, an increase of 12.0% [13]. Innovation Pipeline - The innovative pipeline is expected to continue catalyzing growth, with several drugs in various stages of clinical trials, including JX11502MA for schizophrenia and JX2201 for cardiovascular issues [13].

Core Viewpoint - The news highlights the potential impact of a proposed executive order by the Trump administration aimed at restricting experimental drugs and clinical data from China, which has led to a decline in the stock prices of several Chinese innovative pharmaceutical companies listed in both A-shares and H-shares markets [1][2]. Group 1: Market Reaction - Following the news, stocks of Chinese innovative drug companies such as BeiGene and I-Mab experienced varying degrees of decline in the U.S. market [1]. - The proposed executive order is seen as a response to concerns over China's rise in biotechnology and its implications for the U.S. industry [1][2]. Group 2: Regulatory Implications - The draft order suggests that U.S. pharmaceutical companies will face stricter scrutiny for acquiring drug rights from Chinese firms, requiring mandatory reviews by the Committee on Foreign Investment in the United States (CFIUS) [2]. - The FDA would impose stricter reviews and higher regulatory fees, potentially hindering reliance on clinical trial data from Chinese patients [2][3]. Group 3: Industry Perspectives - Experts indicate that if the order is enacted, it could create higher barriers for licensing agreements between Chinese drug companies and large U.S. pharmaceutical firms, increasing transaction costs and uncertainty [2][3]. - The proposed measures may also disrupt the supply chain and increase R&D costs for U.S. pharmaceutical companies, which rely on innovations developed in China [3][4]. Group 4: Global Context - China has emerged as a significant player in global pharmaceutical innovation, with projections indicating that 93 innovative drugs will be approved in China in 2024, marking a ten-year high [4]. - The country surpassed Japan and Europe in the number of innovative drug approvals, becoming the second-largest region for such approvals globally [4][5]. Group 5: Future Outlook - Despite potential uncertainties due to geopolitical risks, the trend of Chinese innovative drug companies expanding into international markets is expected to continue [5][6]. - Companies are encouraged to enhance their global clinical data capabilities to adapt to changing policies and maintain the value of their innovative drugs [6].

转自：新华财经 新华财经北京9月11日电 （胡晨曦）新华500指数（989001）9月11日收盘涨2.44%，报5020.17点。 走势上看，新华500指数（989001）11日早间微有低开，随后上行翻红，指数全天震荡上扬，最终显著收涨。指数盘中最高触及5020.17点，最低触及4894.73 点，成分股全天总成交额报9448亿元，成交额较上一交易日明显增加。 成分股方面，中际旭创、工业富联、生益科技 、深南电路等成分股涨幅居前；泰格医药、朗新集团、华海药业、恒瑞医药等成分股跌幅靠前。 新华500指数由国家金融信息平台•新华财经发布，新华指数（北京）有限公司运营维护，指数度量A股主要大中市值股票价格水平。关于新华500指数的详 细信息，请参见新华财经客户端。 编辑：王媛媛 ...

Market Overview - The convertible bond market showed positive performance with the Zhongzheng Convertible Bond Index rising by 1.23% to 480.25, with a total trading volume of 76.871 billion [1] - A total of 437 convertible bonds were traded, with 409 increasing in value, 1 remaining flat, and 27 declining [1] Top Performing Convertible Bonds - The top five performing convertible bonds included: - Fushi Convertible Bond (123217) with a rise of 20.0% - Jing 23 Convertible Bond (113669) also up by 20.0% - Jiazhe Convertible Bond (113039) increasing by 17.69% - Chongda Convertible Bond 2 (128131) up by 14.01% - Outong Convertible Bond (not specified) rising by 11.67% [2] Underperforming Convertible Bonds - The five convertible bonds with the largest declines were: - Kaizhong Convertible Bond (113698) down by 3.29% - Yaoshi Convertible Bond (123145) decreasing by 2.92% - Titan Convertible Bond (127096) falling by 2.69% - Huicheng Convertible Bond (not specified) down by 2.04% [2] Corresponding Stock Performance - Among the stocks corresponding to the convertible bonds, 352 stocks rose, 16 remained flat, and 69 declined [1] - The top five performing stocks included: - Si Hui Fushi (300852) with a rise of 19.99% - Jingke Technology (601778) increasing by 10.05% - Chongda Technology (002815) up by 10.01% - Luxshare Precision (not specified) rising by 10.00% - Jingwang Electronics (not specified) also up by 10.00% [4] Declining Stocks - The stocks with the largest declines included: - Titan Shares (not specified) down by 5.64% - Huahai Pharmaceutical (not specified) decreasing by 4.26% - Nenghui Technology (not specified) down by 3.88% - Shouhua Gas (not specified) falling by 2.99% - Shandong Zhanggu (not specified) down by 2.98% [5]

Core Viewpoint - The potential restrictions on Chinese innovative drugs entering the U.S. market have raised concerns, but many companies believe these rumors will not significantly impact their overseas expectations [1][3]. Industry Summary - Major U.S. pharmaceutical companies, including Pfizer and AstraZeneca, have shown a positive attitude towards acquiring Chinese innovative drugs, with Pfizer investing $6 billion in a dual-specific antibody from 3SBio [2]. - In 2024, China's pharmaceutical exports to the U.S. are projected to reach $19.047 billion, with a trade surplus of approximately $3.99 billion [2]. - In the first half of this year, the total value of Chinese innovative drug licensing out reached nearly $66 billion, surpassing the total for the entire year of 2024 [2]. - 38% of significant business development transactions in the U.S. this year involved Chinese drugs, a stark contrast to nearly zero in the previous decade [2]. Company Responses - Several domestic pharmaceutical companies, including Tigermed and Hualan Biological Engineering, have expressed that the recent market fluctuations are related to the rumors but do not foresee immediate impacts on their overseas strategies [3][4]. - Companies like Hualan Biological Engineering and BeiGene have indicated that their current operations remain stable, with ongoing clinical trials and business development plans unaffected by the rumors [5][6]. - The overall sentiment in the industry is one of cautious observation, with experts noting that the actual implementation of any restrictions remains uncertain [5][6].